Acute Beetroot Juice Supplementation in Pre-eclampsia Pregnancies (BEET_PE)
Acute Effect of Beetroot Juice Supplementation in Pregnant Women With Pre-eclampsia: a Single-Blind Randomized Placebo-Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Priscila O Barbosa, Dr
- Phone Number: +55166021000
- Email: barbosapo@usp.br
Study Contact Backup
- Name: Sara T Caetano dos Santos, BSc
- Phone Number: +5511971973623
Study Locations
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazil
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
-
Ribeirão Preto, São Paulo, Brazil, 35180074
- Hospital das Clinicas de Ribeirao Preto
-
Contact:
- Priscila Barbosa, Dr
- Phone Number: +55163602-2800
- Email: barbosapo@usp.br
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Pre-eclampsia pregnat women
Inclusion Criteria:
- Pregnant women at or beyond the 20th week of gestation.
- Hospitalized at Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto.
- Diagnosed with early-onset pre-eclampsia confirmed by a medical professional.
- Capacity to provide written informed consent for study participation.
Exclusion Criteria:
- Multiple pregnancies.
- Uncontrolled arterial hypertension (Systolic Blood Pressure > 160 mmHg or Diastolic Blood Pressure > 100 mmHg).
- Pregnant women with a body mass index > 40 kg/m²
- Severe gestational complications.
- History of food allergy with hypersensitivity to beetroot.
- Smokers.
- Chronic alcohol consumption.
- Medications such as non-steroidal anti-inflammatory drugs, nasal decongestants, users of proton pump inhibitors and H2 receptor antagonists or any other medication that interferes with stomach pH.
- Diagnosis of renal or hepatic disease affecting nitrate metabolism.
- Cardiac conditions such as moderate to severe congestive heart failure and coronary artery disease.
- Pre-existing type 1 or type 2 diabetes.
- Healthy Pregnant Women
Inclusion Criteria:
- Healthy pregnant women at or beyond the 20th week of gestation.
- Absence of pre-eclampsia diagnosis or other obstetric complications.
- Willingness and ability to remain admitted at the Clinical Research Unit for the - period required by the study.
- Capacity to provide written informed consent for study participation.
Exclusion Criteria:
- The same exclusion criteria from Pre-eclampsia group apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Early-onset pre-eclampsia beetroot juice
A single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
|
In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
|
|
Placebo Comparator: Early-onset pre-eclampsia placebo juice
A single dose of 70 ml of a formulation with a similar taste, smell, and texture.
|
In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice.
The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice.
Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
|
|
Experimental: Healthy pregnant woman beetroot juice.
A single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
|
In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
|
|
Placebo Comparator: Healthy pregnant woman placebo juice.
A single dose of 70 ml of a formulation with a similar taste, smell, and texture.
|
In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice.
The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice.
Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute Effect of Beetroot Juice Supplementation on Blood Pressure
Time Frame: At 0, 3, and 6 hours after supplementation, beginning 30 minutes prior to ingestion, compared with a placebo group.
|
Evaluation of the acute effect of beetroot juice supplementation on blood pressure (measured in millimeters of mercury-mmHg) in pregnant women diagnosed with early preeclampsia and in healthy pregnant women.
|
At 0, 3, and 6 hours after supplementation, beginning 30 minutes prior to ingestion, compared with a placebo group.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma Concentrations of Nitric Oxide Metabolites
Time Frame: At 0, 3, and 6 hours after supplementation compared with a placebo group.
|
Assessment of plasma concentrations of nitric oxide metabolites (nitrite, nitrate and nitrosothiol) in pregnant women diagnosed with pre-eclampsia, comparing those receiving beetroot juice supplementation and those receiving placebo.
|
At 0, 3, and 6 hours after supplementation compared with a placebo group.
|
|
Plasma Lipid Peroxidation Levels
Time Frame: At 0, 3, and 6 hours after supplementation compared with a placebo group.
|
Assessment of the degree of lipid peroxidation, measured by the level of malondialdehyde in each study group.
|
At 0, 3, and 6 hours after supplementation compared with a placebo group.
|
|
Concentration of Total Antioxidant Capacity in Plasma
Time Frame: At 0, 3, and 6 hours after supplementation compared with a placebo group.
|
Determination of the plasma concentration of total antioxidant capacity of plasma, measured in Trolox equivalent antioxidant capacity, in each study group.
|
At 0, 3, and 6 hours after supplementation compared with a placebo group.
|
|
Maternal Blood Flow Velocity
Time Frame: 3 hours post-supplementation of beetroot juice or placebo.
|
Maternal blood flow velocity will be measured in centimeters per second (cm/s) using Doppler ultrasound, in each study group.
|
3 hours post-supplementation of beetroot juice or placebo.
|
|
Fetal Heart Rate
Time Frame: 3 hours post-supplementation of beetroot juice or placebo.
|
Fetal heart rate will be measured in beats per minute (bpm) using Doppler ultrasound, in each study group.
|
3 hours post-supplementation of beetroot juice or placebo.
|
|
Umbilical Arterial Pulsatility Index
Time Frame: 3 hours post-supplementation of beetroot juice or placebo.
|
The umbilical arterial pulsatility index will be calculated and reported as a percentile, in each group.
|
3 hours post-supplementation of beetroot juice or placebo.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ricardo C Cavalli, Dr, Medical School of Ribeirao Preto, USP
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024/823
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.